Alesta Therapeutics Advances ALE2 to Target Rare Forms of CMT

Alesta Therapeutics Advances ALE2 to Target Rare Forms of CMT

Alesta Therapeutics, a proud collaborator in the Hereditary Neuropathy Foundation’s (HNF) Therapeutic Research in Accelerated Discovery (TRIAD) program, is spearheading groundbreaking research to address Charcot-Marie-Tooth (CMT) disease. Their innovative therapy, ALE2, is an experimental oral treatment aimed at rare forms of CMT caused by mutations in glycyl-tRNA and tyrosyl-tRNA synthetase genes. These genetic mutations disrupt nerve function, leading to progressive muscle weakness, sensory loss, and limb deformities that impact over 10,000 individuals in the U.S., Europe, and Japan.

ALE2 focuses on inhibiting GCN2, a stress response pathway that becomes overactive due to these mutations, resulting in chronic nerve toxicity. Early preclinical research indicates that ALE2 could effectively slow or halt the progression of these debilitating symptoms, offering new hope for patients with these rare forms of CMT.

With a recent $67 million funding round, Alesta Therapeutics is fast-tracking ALE2’s development toward clinical trials. As a TRIAD partner, Alesta is committed to working closely with researchers, clinicians, and advocacy organizations to ensure its efforts align with the needs of the CMT community.

“All of us at HNF are inspired by Alesta’s commitment to tackling the unmet needs of those living with rare forms of CMT,” said Allison Moore, HNF Founder and CEO. “Innovative partnerships like these exemplify our mission to deliver treatments and cures for CMT in our lifetime.”

Join GRIN and Make an Impact!

Through cutting-edge science and collaborative partnerships, Alesta Therapeutics is taking significant strides toward transforming care for individuals affected by CMT.

HNF’s Global Registry for Inherited Neuropathies (GRIN) empowers researchers with patient-driven data to accelerate breakthroughs like Alesta Therapeutics’ ALE2. By joining GRIN, you contribute to vital research, uncovering disease patterns, and advocating for resources to support all forms of CMT.

Be part of the movement transforming care and bringing hope to those affected by CMT.